keyword
MENU ▼
Read by QxMD icon Read
search

Urothelial carcinoma

keyword
https://www.readbyqxmd.com/read/28345830/histopathologic-evolution-of-urothelial-carcinoma-recurrence-in-transurethral-resection-of-the-urinary-bladder-35-consecutive-cases-and-literature-review
#1
Ali Koyuncuer
Background: Urothelial carcinoma (UC) is the malignancy most frequently encountered in the urinary bladder.The primary aim of this study was to make a reappraisal of histopathologic features, recurrence and progression. Materials and Methods: The records of cases consecutively diagnosed with UC in the state hospital pathology laboratory were collected. Cases were classified according to age, gender, histologic grade, pathologic staging [primary Tumor (pT)] ,tumor configuration, primary or recurrent status, and progression...
February 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28343326/segmental-ureterectomy-is-not-inferior-to-radical-nephroureterectomy-for-either-middle-or-distal-ureter-urothelial-cell-carcinomas-within-3-5%C3%A2-cm
#2
Chen Fang, Xin Xie, Tianyuan Xu, Wei He, Hongchao He, Xiaojing Wang, Yu Zhu, Zhoujun Shen, Yuan Shao
OBJECTIVE: To evaluate oncologic outcomes of segmental ureterectomy (SU) compared with radical nephroureterectomy (RNU) for urothelial carcinoma of ureter. To evaluate whether tumor position is a factor to influence outcomes of different surgical procedures. METHODS: From November 2003 to June 2016, 131 patients with urothelial carcinoma of ureter underwent SU or RNU at our department. We used survival analysis and Cox regression models to compare oncologic outcomes after SU and RNU...
March 25, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28342936/clinical-outcomes-in-patients-with-panurothelial-carcinoma-treated-with-radical-nephroureterectomy-following-cystectomy-for-metachronous-recurrence
#3
Qiang Li, Melissa Assel, Eugene Pietzak, Aditya Bagrodia, Eugene Cha, Guido Dalbagni, Jonathan Coleman
PURPOSE: We report pathologic, functional, and oncologic outcomes in patients treated with radical nephroureterectomy following radical cystectomy. MATERIALS AND METHODS: We identified patients who underwent radical cystectomy then radical nephroureterectomy for metachronous urothelial recurrence at our institution between January 1995 and December 2014. Univariable Cox regression was used to assess the association between overall survival and age, grade, stage, lymph node metastasis, and radiographic findings...
March 22, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28342451/tert-promoter-mutations-in-telomere-biology
#4
REVIEW
Barbara Heidenreich, Rajiv Kumar
Telomere repeats at chromosomal ends, critical to genome integrity, are maintained through an elaborate network of proteins and pathways. Shelterin complex proteins shield telomeres from induction of DNA damage response to overcome end protection problem. A specialized ribonucleic protein, telomerase, maintains telomere homeostasis through repeat addition to counter intrinsic shortcomings of DNA replication that leads to gradual sequence shortening in successive mitoses. The biogenesis and recruitment of telomerase composed of telomerase reverse transcriptase (TERT) subunit and an RNA component, takes place through the intricate machinery that involves an elaborate number of molecules...
January 2017: Mutation Research
https://www.readbyqxmd.com/read/28342221/p53-immunohistochemistry-in-high-grade-urothelial-carcinoma-of-the-bladder-is-prognostically-significant
#5
Anjelica Hodgson, Bin Xu, Michelle R Downes
AIMS: TP53 mutations are characteristic of the high grade pathway in the dual pathway of urothelial carcinogenesis. These mutations have been correlated with aberrant accumulation of p53 protein, however the definition and significance of this varies in the literature. We assessed p53 immunostaining in a cohort of high grade urothelial carcinomas using standard published cut offs and a novel binarized method which included assessment of the null phenotype. Each scoring method was correlated with oncologic outcome...
March 25, 2017: Histopathology
https://www.readbyqxmd.com/read/28341930/clinical-utility-of-cxbladder-for-the-diagnosis-of-urothelial-carcinoma
#6
David Darling, Carthika Luxmanan, Paul O'Sullivan, Tony Lough, James Suttie
INTRODUCTION: This study aimed to demonstrate the clinical utility of non-invasive multigene Cxbladder urine tests in reducing the overall number of diagnostic tests and invasive procedures used in the clinical evaluation of patients presenting with microhematuria, a key symptom of urothelial carcinoma (UC). There is a belief that using non-invasive molecular diagnostic tests in patients with hematuria may lead to patients undergoing unnecessary and costly invasive procedures that can cause adverse events and decrease patient quality of life...
March 24, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28341322/re-clonal-evolution-of-chemotherapy-resistant-urothelial-carcinoma
#7
Kerstin Junker, Carsten-Henning Ohlmann
No abstract text is available yet for this article.
March 21, 2017: European Urology
https://www.readbyqxmd.com/read/28339163/next-generation-sequencing-of-urine-specimens-a-novel-platform-for-genomic-analysis-in-patients-with-non-muscle-invasive-urothelial-carcinoma-treated-with-bacille-calmette-gu%C3%A3-rin
#8
Sasinya N Scott, Irina Ostrovnaya, Caroline M Lin, Nancy Bouvier, Bernard H Bochner, Gopakumar Iyer, David Solit, Michael F Berger, Oscar Lin
BACKGROUND: Biopsies from patients with high-risk (HR) non-muscle-invasive urothelial carcinoma (NMIUC), especially flat urothelial carcinoma in situ, frequently contain scant diagnostic material or denuded mucosa only, and this precludes further extensive genomic analysis. This study evaluated the use of next-generation sequencing (NGS) analysis of urine cytology material from patients with HR NMIUC in an attempt to identify genetic alterations that might correlate with clinical features and responses to bacille Calmette-Guérin (BCG) treatment...
March 24, 2017: Cancer
https://www.readbyqxmd.com/read/28334788/impact-of-divergent-differentiation-in-urothelial-carcinoma-on-oncological-outcome-in-patients-with-t1-high-grade-bladder-cancer
#9
Nakanori Fujii, Yoshinobu Hoshii, Hiroshi Hirata, Junichi Mori, Kosuke Shimizu, Keita Kobayashi, Yoshihisa Kawai, Ryo Inoue, Yoshiaki Yamamoto, Hiroaki Matsumoto, Kazuhiro Nagao, Hideyasu Matsuyama
Objective: T1 high-grade bladder cancer has a poor prognosis compared with other non-muscle-invasive bladder cancers. We investigated the clinical outcomes among patients with T1 high-grade bladder cancer to identify factors related to cancer recurrence and disease progression. Methods: We retrospectively reviewed the data of 148 patients who were diagnosed with T1 high-grade bladder cancer by transurethral resection from January 2001 to February 2015 at our institution...
March 8, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28333147/solute-carrier-family-12-member-5-promotes-tumor-invasion-metastasis-of-bladder-urothelial-carcinoma-by-enhancing-nf-%C3%AE%C2%BAb-mmp-7-signaling-pathway
#10
J Y Liu, Y B Dai, X Li, K Cao, D Xie, Z T Tong, Z Long, H Xiao, M K Chen, Y L Ye, B Liu, J Tan, J Tang, Z Z Xu, Y Gan, Y H Zhou, F Deng, L Y He
Solute carrier family 12 member 5 (SLC12A5), an integral membrane KCl cotransporter, which maintains chloride homeostasis in neurons, is aberrantly expressed and involved in the tumorigenesis of certain cancers. However, the clinical significance and biological role of SLC12A5 in human bladder urothelial carcinoma (BUC) remains unclear. In this study, the expression of SLC12A5 was examined in clinical specimens of primary BUC and in BUC cell lines using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR), western blot and immunohistochemistry (IHC)...
March 23, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/28333021/a-phase-1-2-trial-of-a-combination-of-paclitaxel-and-trastuzumab-with-daily-irradiation-or-paclitaxel-alone-with-daily-irradiation-after-transurethral-surgery-for-noncystectomy-candidates-with-muscle-invasive-bladder-cancer-trial-nrg-oncology-rtog-0524
#11
M Dror Michaelson, Chen Hu, Huong T Pham, Douglas M Dahl, Chin Lee-Wu, Gregory P Swanson, Jacqueline Vuky, R Jeffrey Lee, Luis Souhami, Brian Chang, Asha George, Howard Sandler, William Shipley
PURPOSE: Bladder preservation therapy is an effective treatment for muscle-invasive urothelial carcinoma (UC). In this study we treated noncystectomy candidates with daily radiation and weekly paclitaxel for 7 weeks. Patients whose tumors showed her2/neu overexpression were additionally treated with weekly trastuzumab. METHODS AND MATERIALS: Sixty-eight evaluable patients were treated with radiation therapy and either paclitaxel + trastuzumab (group 1) or paclitaxel alone (group 2)...
April 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28332428/dramatic-impact-of-blood-transfusion-on-cancer-specific-survival-after-radical-cystectomy-irrespective-of-tumor-stage
#12
Alexander Buchner, Tobias Grimm, Birte-Swantje Schneevoigt, Georg Wittmann, Alexander Kretschmer, Friedrich Jokisch, Markus Grabbert, Maria Apfelbeck, Gerald Schulz, Christian Gratzke, Christian G Stief, Alexander Karl
OBJECTIVE: The aim of the present study was to determine the influence of intraoperative and postoperative blood transfusion on cancer-specific outcome. MATERIALS AND METHODS: Follow-up data were collected from 722 patients undergoing radical cystectomy for urothelial carcinoma of the bladder (UCB) between 2004 and 2014. Median follow-up was 26 months (interquartile range 12-61 months). Outcome was analyzed in relation to the amount of intraoperative and postoperative blood transfusion and different tumor stages...
March 23, 2017: Scandinavian Journal of Urology
https://www.readbyqxmd.com/read/28331342/spotlight-on-atezolizumab-and-its-potential-in-the-treatment-of-advanced-urothelial-bladder-cancer
#13
REVIEW
Ahmet Murat Aydin, Solomon L Woldu, Ryan C Hutchinson, Martin Boegemann, Aditya Bagrodia, Yair Lotan, Vitaly Margulis, Laura-Maria Krabbe
Metastatic urothelial carcinoma of the bladder is an aggressive malignancy with poor prognosis, reflecting a lack of effective systemic therapies. The current standard of care includes multiagent platinum-based chemotherapy; however a majority of patients do not respond to treatment and most eventually succumb to disease. Recently, renewed interest in immunotherapy in the form of immune-checkpoint inhibition has gained widespread attention for a number of malignancies. Atezolizumab, an anti-PDL1 antibody, has been shown to be effective in a subset of patients previously treated with or unfit for platinum-based chemotherapy, and has shown durable responses with a good tolerability profile...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28328001/cancer-vaccines-at-the-age-of-immune-checkpoint-inhibitors-reasonable-approach-as-combination-therapy-in-advanced-urothelial-carcinoma
#14
Petros Grivas, Vadim S Koshkin, Sumanta K Pal
No abstract text is available yet for this article.
February 21, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28327458/nfatc1-expression-as-a-prognosticator-in-urothelial-carcinoma-of-the-upper-urinary-tract
#15
Takashi Kawahara, Satoshi Inoue, Kazutoshi Fujita, Taichi Mizushima, Hiroki Ide, Seiji Yamaguchi, Hiroaki Fushimi, Norio Nonomura, Hiroshi Miyamoto
We recently found that NFATc1, a member of the NFAT family and a key regulator of the immune response, could induce bladder carcinogenesis and cancer progression. In this study, we immunohistochemically stained for NFATc1 in upper urinary tract urothelial carcinoma (UUTUC) specimens and paired nonneoplastic urothelial tissues. NFATc1 was positive in 51 [52%; 40 (40%) weak (1+), 9 (9%) moderate (2+), and 2 (2%) strong (3+)] of 99 UUTUCs, which was significantly higher than in benign urothelium [30 (36%) of 83; 28 (34%) weak and 2 (2%) moderate] (0 vs 1+/2+/3+, P=...
March 16, 2017: Translational Oncology
https://www.readbyqxmd.com/read/28327194/upregulation-of-the-long-noncoding-rna-uca1-affects-the-proliferation-invasion-and-survival-of-hypopharyngeal-carcinoma
#16
Ye Qian, Dayu Liu, Shengda Cao, Ye Tao, Dongmin Wei, Wenming Li, Guojun Li, Xinliang Pan, Dapeng Lei
BACKGROUND: Several long noncoding RNAs (lncRNAs) are involved in oncogenesis. METHODS AND RESULTS: Our microarray analysis showed that numerous lncRNAs are dysregulated in hypopharyngeal squamous cell carcinoma (HSCC) tumor tissues as compared with normal tissues. Among those lncRNAs, urothelial carcinoma-associated 1 (UCA1) has been found to have an oncogenic role in HSCC. We confirmed the upregulation of UCA1 in HSCC by assessing its expression levels in a cohort of 53 patient tumors and paired non-tumor samples...
March 21, 2017: Molecular Cancer
https://www.readbyqxmd.com/read/28323779/gata3-and-myb-expression-in-cutaneous-adnexal-neoplasms
#17
Joana Pardal, Uma Sundram, M Angelica Selim, Mai P Hoang
Knowledge of staining pattern of certain immunostains might be useful in the classification of cutaneous adnexal tumors that can have clinical importance. We studied GATA3 and MYB expression in archival materials of 220 adnexal tumors comprised of sebaceous carcinomas, follicular tumors, apocrine carcinoma, predominantly apocrine tumors, predominantly eccrine tumors, and others including adenoid cystic carcinomas. Nuclear GATA3 expression was seen in 70% (153/220) of cases, including sebaceous carcinoma (93%), apocrine carcinoma (93%), follicular neoplasms (100%), and predominantly apocrine neoplasms (69%), yet only 38% of predominantly eccrine neoplasms...
April 2017: American Journal of Dermatopathology
https://www.readbyqxmd.com/read/28322594/development-of-endoscopic-diagnosis-and-treatment-for-chronic-unilateral-hematuria-35-years-experience
#18
Ryuta Tanimoto, Hiromi Kumon, Demetrius H Bagley
PURPOSE: Chronic unilateral hematuria (CUH) is also called lateralizing essential hematuria, benign essential hematuria, and benign lateralizing hematuria, which was defined as intermittent or continuous gross hematuria that cannot be diagnosed with standard radiology and hematology studies, together with unilateral bloody efflux by cystoscopy. CUH is rare, but sometimes confused with malignancy or life threatening hemorrhage. Therefore, it can cause considerable anxiety to not only patients but also urologists...
March 21, 2017: Journal of Endourology
https://www.readbyqxmd.com/read/28321462/-when-is-surgical-treatment-indicated-in-metastatic-urothelial-carcinoma-and-what-is-the-scientific-rationale
#19
C Niedworok, H Rübben
BACKGROUND: Patients with metastatic urothelial carcinoma have a poor prognosis. Standard of care is a systemic chemotherapy but surgical excision of metastasis can be performed in individual approaches. OBJECTIVES: To evaluate treatment options and study results and to identify and discuss advantages and disadvantages of metastasectomy in urothelial carcinoma. MATERIALS AND METHODS: Database analysis and discussion of clinical trials concerning metastasectomy in urothelial carcinoma...
March 20, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28319171/a-reported-20-gene-expression-signature-to-predict-lymph-node-positive-disease-at-radical-cystectomy-for-muscle-invasive-bladder-cancer-is-clinically-not-applicable
#20
Kim E M van Kessel, Harmen J G van de Werken, Irene Lurkin, Angelique C J Ziel-van der Made, Ellen C Zwarthoff, Joost L Boormans
BACKGROUND: Neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) provides a small but significant survival benefit. Nevertheless, controversies on applying NAC remain because the limited benefit must be weight against chemotherapy-related toxicity and the delay of definitive local treatment. Therefore, there is a clear clinical need for tools to guide treatment decisions on NAC in MIBC. Here, we aimed to validate a previously reported 20-gene expression signature that predicted lymph node-positive disease at radical cystectomy in clinically node-negative MIBC patients, which would be a justification for upfront chemotherapy...
2017: PloS One
keyword
keyword
19765
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"